Baird Maintains Bio-Techne(TECH.US) With Buy Rating, Maintains Target Price $82
Optimistic Growth and Improved Financial Outlook for Bio-Techne: A Buy Recommendation
Scotiabank Maintains Bio-Techne(TECH.US) With Buy Rating, Maintains Target Price $83
Scotiabank Reaffirms Their Buy Rating on Bio-Techne (TECH)
Bio-Techne Price Target Maintained With a $95.00/Share by Benchmark
Bio-Techne Analyst Ratings
Benchmark Co. Maintains Bio-Techne(TECH.US) With Buy Rating, Maintains Target Price $95
Benchmark Co. Remains a Buy on Bio-Techne (TECH)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (TECH), Pediatrix Medical Group (MD) and Arcus Biosciences (RCUS)
Buy Rating Affirmed for Bio-Techne on Strong Consumables Foundation and Market Growth Potential
RBC Capital Maintains Sector Perform on Bio-Techne, Lowers Price Target to $70
Stephens Adjusts Price Target on Bio-Techne to $85 From $90
RBC Capital Keeps Their Hold Rating on Bio-Techne (TECH)
Bio-Techne Analyst Ratings
Baird Maintains Outperform on Bio-Techne, Raises Price Target to $82
Citi Downgrades Bio-Techne to Neutral, Cites Valuation
Citi: Bio-Techne (TECH.US) rating downgraded from buying to neutral, with a target price of $85.00.
Bio-Techne Analyst Ratings
Citigroup Downgrades Bio-Techne to Neutral From Buy, With $85 Price Target
Argus Adjusts Price Target on Bio-Techne to $95 From $90, Keeps Buy Rating